These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 30796703)

  • 21. Hsp90 inhibitor, BIIB021, induces apoptosis and autophagy by regulating mTOR-Ulk1 pathway in imatinib-sensitive and -resistant chronic myeloid leukemia cells.
    He W; Ye X; Huang X; Lel W; You L; Wang L; Chen X; Qian W
    Int J Oncol; 2016 Apr; 48(4):1710-20. PubMed ID: 26892093
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neferine in the Lotus Plumule Potentiates the Antitumor Effect of Imatinib in Primary Chronic Myeloid Leukemia Cells In Vitro.
    Zhang Y; Xiao Y; Dong Q; Ouyang W; Qin Q
    J Food Sci; 2019 Apr; 84(4):904-910. PubMed ID: 30866043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Celecoxib suppresses autophagy and enhances cytotoxicity of imatinib in imatinib-resistant chronic myeloid leukemia cells.
    Lu Y; Liu LL; Liu SS; Fang ZG; Zou Y; Deng XB; Long ZJ; Liu Q; Lin DJ
    J Transl Med; 2016 Sep; 14():270. PubMed ID: 27645552
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5.
    Chen Y; Zhou Q; Zhang L; Zhong Y; Fan G; Zhang Z; Wang R; Jin M; Qiu Y; Kong D
    Oncotarget; 2017 Apr; 8(17):28906-28921. PubMed ID: 28423649
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of cancer stem cells in chronic myeloid leukaemia.
    Jørgensen HG; Holyoake TL
    Biochem Soc Trans; 2007 Nov; 35(Pt 5):1347-51. PubMed ID: 17956348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inhibition of Siah2 Ubiquitin Ligase by Vitamin K3 Attenuates Chronic Myeloid Leukemia Chemo-Resistance in Hypoxic Microenvironment.
    Huang J; Lu Z; Xiao Y; He B; Pan C; Zhou X; Xu N; Liu X
    Med Sci Monit; 2018 Feb; 24():727-735. PubMed ID: 29400343
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic characteristics of imatinib resistance in chronic myeloid leukaemia cells.
    Klawitter J; Kominsky DJ; Brown JL; Klawitter J; Christians U; Leibfritz D; Melo JV; Eckhardt SG; Serkova NJ
    Br J Pharmacol; 2009 Sep; 158(2):588-600. PubMed ID: 19663881
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Distinct Dasatinib-Induced Mechanisms of Apoptotic Response and Exosome Release in Imatinib-Resistant Human Chronic Myeloid Leukemia Cells.
    Liu J; Zhang Y; Liu A; Wang J; Li L; Chen X; Gao X; Xue Y; Zhang X; Liu Y
    Int J Mol Sci; 2016 Apr; 17(4):531. PubMed ID: 27070592
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
    Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
    Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
    Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(-) population to imatinib.
    Airiau K; Mahon FX; Josselin M; Jeanneteau M; Turcq B; Belloc F
    Exp Hematol; 2012 May; 40(5):367-78.e2. PubMed ID: 22240609
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biochemical and chemical characterization of Cynara cardunculus L. extract and its potential use as co-adjuvant therapy of chronic myeloid leukemia.
    Russo A; Perri M; Cione E; Di Gioia ML; Nardi M; Cristina Caroleo M
    J Ethnopharmacol; 2017 Apr; 202():184-191. PubMed ID: 28323047
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
    Tsubaki M
    Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Homoharringtonine suppresses imatinib resistance via the Bcl-6/p53 pathway in chronic myeloid leukemia cell lines.
    Wang Q; Ding W; Ding Y; Ma J; Qian Z; Shao J; Li Y
    Oncotarget; 2017 Jun; 8(23):37594-37604. PubMed ID: 28410239
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The novel anticancer agent JNJ-26854165 is active in chronic myeloid leukemic cells with unmutated BCR/ABL and T315I mutant BCR/ABL through promoting proteosomal degradation of BCR/ABL proteins.
    You L; Liu H; Huang J; Xie W; Wei J; Ye X; Qian W
    Oncotarget; 2017 Jan; 8(5):7777-7790. PubMed ID: 27999193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Induction of apoptosis in imatinib sensitive and resistant chronic myeloid leukemia cells by efficient disruption of bcr-abl oncogene with zinc finger nucleases.
    Huang N; Huang Z; Gao M; Luo Z; Zhou F; Liu L; Xiao Q; Wang X; Feng W
    J Exp Clin Cancer Res; 2018 Mar; 37(1):62. PubMed ID: 29554925
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PBA2, a novel inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
    Gupta P; Kathawala RJ; Wei L; Wang F; Wang X; Druker BJ; Fu LW; Chen ZS
    Cancer Lett; 2016 Dec; 383(2):220-229. PubMed ID: 27720778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dual inhibition of Bcr-Abl and Hsp90 by C086 potently inhibits the proliferation of imatinib-resistant CML cells.
    Wu L; Yu J; Chen R; Liu Y; Lou L; Wu Y; Huang L; Fan Y; Gao P; Huang M; Wu Y; Chen Y; Xu J
    Clin Cancer Res; 2015 Feb; 21(4):833-43. PubMed ID: 25501124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells.
    Chen Y; Zhou Q; Zhang L; Wang R; Jin M; Qiu Y; Kong D
    Oncol Rep; 2016 Dec; 36(6):3643-3650. PubMed ID: 27748929
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
    Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
    Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.